ABSTRACT. "Uteroplacental insufficiency" often causes asymmetric fetal growth retardation. Glucose transporters control cell glucose utilization and thus may be critical in the control of fetal growth. We hypothesized that uteroplacental insufficiency might alter glucose transporter activity, protein, and gene expression and thereby affect discordant organ growth in small-for-gestational-age (SGA) fetuses. We performed bilateral uterine artery ligation in pregnant rats on d 19 of gestation (term-21.5 d) to cause uteroplacental insufficiency and obtained fetal brain and lung tissue on d 20. The brain mass of SGA fetuses did not differ from that of sham and normal fetuses, but lung mass was significantly diminished. Glucose transport, measured with [3H]2-deoxyglucose, was similar in glial cells and brain tissue of SGA, sham, and normal fetuses. In contrast, type I1 pneumocytes, lung fibroblasts, and lung tissue of SGA fetuses had significantly decreased glucose transport. The intrinsic activity of the glucose transporter (Km) was not altered in the brain or lung of SGA fetuses. Total glucose transporter protein measured by cytochalasin-B binding and glucose transporter 1 mRNA was diminished in SGA lung tissue and type I1 pneumocytes, but not in SGA brain tissue or glial cells. W e could not detect glucose transporter 3 mRNA in significant quantity in any tissue. With uteroplacental insufficiency, glucose transport is differentially altered in lung and brain. Glucose transporter protein and gene expression are diminished in the lung and normal in the brain of SGA fetuses. These changes may contribute to fetal growth retardation and the phenomenon of "brain sparing." (Pediatr Res 31: 59-63, 1992) Abbreviations SGA, small for gestational age 2-DG, 2-deoxyglucose In previous studies we quantitated factors responsible for fetal growth retardation by performing bilateral uterine artery ligation in the maternal rat (I). This technique, an extreme example of uteroplacental insufficiency, restricts glucose and amino acid availability and alters a number of physiologic variables in the fetus including gaseous exchange (2) . Glucose is one of several important metabolic fuels for the fetus, and limitation of its availability and utilization is probably involved in retarding fetal growth.
In most fetal tissues, glucose uptake is controlled by a facilitated transport mechanism. Glucose transporters are a family of structurally related proteins encoded by distinct genes and expressed in a tissue-specific manner (3) (4) (5) . cDNA encoding a glucose transporter have been cloned from both rat brain and human hepatoma (Hep G2) cell libraries (6, 7) . This glucose transporter has been termed Glut 1 and is present in most fetal tissues including brain (8, 9) . Glut 3, originally cloned from human fetal skeletal muscle, has been found in small quantities in fetal rabbit brain (9) .
How uteroplacental insufficiency affects glucose transport in the fetus and thereby contributes to the development of growth retardation is unknown. Several in vivo studies using 2-deoxyglucose in the pregnant rat have demonstrated limited glucose transfer to the fetus after maternal uterine artery ligation (10, 1 I).
When substrate supply is limited to the fetus, tissue-specific regulation of glucose transporters might ration glucose availability to organs. In this manner, glucose transport and glucous transporter gene expression might differ between brain and other tissues, and this might in part be responsible for brain sparing in the SGA fetus. To address this possibility, we measured glucose transporter activity, total glucose transporter protein, and glucose transporter mRNA in freshly isolated brain and lung tissue and in cultured cell monolayers of brain and lung from SGA and normal rat fetuses. Glial cells, type I1 pneumocytes, and lung fibroblasts represent major cellular components of brain and lung and have important metabolic functions. We compared brain to lung because in the SGA fetal rat the brain has high metabolic activity and growth sparing, whereas the lung is less When "uteroplacental insufficiency" complicates a pregnancy, metabolically active and has decreased growth, asymmetric fetal growth retardation develops. Under such conWe found that glucose transporter activity, protein, and ditions, overall somatic growth is retarded but gross brain growth mRNA do not differ in the brain of S G~ and normal fetuses, In remains normal. The mechanisms responsible for the phenom-contrast, lungs of SGA fetuses have significantly diminished enon of "brain sparing" are not well understood.
glucose transport. These data suggest that under conditions of Culture and isola~ion ofglial cells, type II pneumocytes, and lungfibrohlasts. The brains were removed under sterile conditions and dissociated with 0.25% trypsin and DNase (10 pg/mL) (1 2, 13). The cells were plated on poly-L-lysine coated plates and maintained at 37" C in a humidified atmosphere of 95% air and 5% C02. At 72 h, the plates were washed, and the resultant adherent cells were trypsinized, replated, and grown in Dulbecco's modified Eagle's medium with 10% FCS. The cells were incubated for 6 d in Dulbecco's modified Eagle's medium supplemented with 10% FCS before use in glucose transport experiments. Media was changed every 1-2 d. Determinations of purity of glial cell cultures by staining with glial fibrillary protein (95%) were made just before their use in experiments.
Lungs were removed and dissected under sterile conditions. The trachea and major airways were removed, and the remaining tissue was chopped into 1-mm3 cubes. Tissue from an entire litter was pooled. Explants were cultured for 24 h in serum-free Waymouth's media (2 mL/dish) at 37°C in a humidified atmosphere of 95% air and 5% COz (10). The tissue was harvested, and a cell suspension was made by incubating the tissue with a trypsinizing solution (14, 15) . A differential adherence method was used for separating type I1 pneumocytes from fibroblasts (14, 15) . After 48 h culture in minimal essential medium supplemented with 10% FCS, the plates were rinsed with PBS and the confluent monolayers of pneumocytes were used for transport experiments. Hematoxylin-LiCOs staining was used to confirm purity (at least 90% pure) of the type I1 pneumocytes just before their use in experiments. Lung fibroblasts were grown in minimal essential medium supplemented with 10% FCS for 5-7 d before use in transport experiments. Media was changed daily in the type I1 pneumocyte and fibroblast cultures.
Membrane preparation. Membranes were prepared from uncultured brain and lung tissue and glial cells, type I1 pneumocytes, and lung fibroblasts. Brains and lungs were dissected from fetal rats and extensively washed to remove red blood cells. Tissues and cell monolayers were washed, placed in ice-cold isolation buffer (250 mM sucrose, 2 mM EDTA, 10 mM TrisHCl, 1.5 mM phenylmethylsulfonylfluoride, 25 mM benzamidine, 2 pM leupeptin, 2 pM pepstatin, and 500 kallikrein inhibitor units/mL aprotinin), and homogenized with a small Polytron probe for 6 s (tissue) or a Virtis (Virtis Co., Gardiner, NY) sonicator (cell monolayers). The homogenates were centrifuged at 5000 x g for 5 min at 4"C, and the supernatant was centrifuged at 100 000 x g for 90 min at 4°C. The pellet was suspended in cold isolation buffer by several passes through a 22-gauge needle. Protein was determined by the method of Lowry (1 5).
Glucose transport. 2-DG transport studies were performed in fresh brain and lung tissue, cultured glial cells, type I1 pneumocytes, and lung fibroblasts from SGA, sham, and normal fetal rats on d 20 of gestation. These methods have been described previously (1 6). Cultured monolayers of type I1 pneumocytes, lung fibroblasts, and glial cells, were washed with 10 mL of 37°C PBS. Glucose transport was initiated by adding [3H]2-DG to the incubation media [incubation media: 900 pL PBS, 100 pL [3H] 2-DG (0.16 mM, 1 pCi/mL)]. 2-DG, a glucose analog, enters the cell and is phosphorylated but not further metabolized. Thus, the uptake of 2-DG into cells reflects both transport and phosphorylation of glucose. Transport rather than phosphorylation has been determined to be the rate-limiting step of 2-DG uptake in brain and lung (1 7, 18) . Therefore, determination of 2-DG uptake into brain and lung cells is a valid measurement of glucose transport. Cells were incubated for different periods (0, 0.5, 1, 5, 10, 15, and 20 min). At the end of each period, transport was stopped by the addition of ice-cold PBS. Cells were washed and solubilized with 1% Triton. An aliquot from this was used for determination of radioactivity and for determination of DNA. Noncarrier-mediated transport was determined by adding 10 pM cytochalasin B (maximal inhibitory concentration in all three cell types), a fungal metabolite that is a specific and competitive inhibitor of glucose transport, to the incubation media. 2-DG uptake was then determined. The final concentration of ethanol in the solution was less than 1 %. Nonspecific binding of glucose was determined by adding 1000-fold excess of unlabeled 2-DG to the incubation media. Nonspecific binding and noncaniermediated transport were subtracted to determine specific transport. The addition of cytochalasin B to the cell cultures inhibited transport of 2-DG by 85% in the brain cells, 65% in the type I1 pneumocytes, and 90% in lung fibroblasts. To determine the kinetics of glucose transport, the cell monolayers were incubated with 0.5, 1, 2, 5, 10, and 20 mM 2-DG, and glucose transport was determined as described above.
For glucose transport experiments done in uncultured tissue, brains and lungs were chopped and 100 mg of tissue were placed in 35-mL sterile plastic tubes and centrifuged for 5 min. Glucose transport was determined at 0, 10, 20, 40, and 60 min ( n = 7 experiments). We used [3H]inulin to determine extracellular water space.
Transport was related to DNA and protein content. DNA content was determined by fluorometric assay (19) .
Cytochalasin-B binding. We used cytochalasin-B binding studies to quantitate glucose transporter protein (20) (21) (22) Northern and slot-blot analysis. Total RNA was extracted using RNazol (guanidinium thiocyanate, phenol, 2-mercaptoethanol; Cinna/Biotecx, Friendswood, TX). RNA (10 pg) was fractionated by 1.2% agarose-6.6% formaldehyde gels and transferred to Nytran filters (Schleicher & Schell, Keene, NH) (24) . The gel was stained with ethidium bromide and visualized under UV light. RNA was fixed to the filter by baking for 2 h at 180°C. The filters were prehybridized for 3 h at 42°C in 50% formamide, 5 x SSC (3 M NaCl, 3 M Na3 citrate.2 H20), 1 % glycine, 5 x Denhardt's solution (0.02% each of Ficoll 400, polyvinylpyrrolidone, and BSA), 100 pg of herring sperm DNA, and 100 pg torula yeast RNA. A full-length 2.8-kb rat brain D-glucose transporter cDNA (Glut 1) in the plasmid pGEM and the 493-bp Glut 3 cDNA (cloned from mouse) (both kindly provided by G. Bell) were labeled with 32P dCTP (Amersham, Arlington Heights, IL) with random oligonucleotide primers (Pharmacia Oligo was similar in sham and normal fetuses.
Transport of 2-DG was linear up to 10 min in type I1 pneumoTotal protein and DNA content did not differ significantly cfles , (Fig. 4) and lung fibroblasts. o f note, 2-DG uptake was among SGA, sham, and glial cells, type 11 pneumocfles, and inhibited only 65% by 10 fiM cytochalasin B. Because c~tochal-lung fibroblasts.
asin B only inhibits facilitated glucose transport, it is likely that Transport of 2-DG in glial cells was linear at 3 7 "~ for at least approximately 35% of 2-DG uptake is via ~a + -c o u~l e d glucose 15 min and then reached saturation by 20 min (Fig. 1) (Table 1) . Therefore, the rate of V,,, than shams and normals, The difference in V,,, among 2-DG and its for the glucose are SGA, shams, and normals was even greater in lung fibroblasts. similar in SGA, sham, and normal glial cells. V,,, was four times less in SGA compared to normal fibroblasts. The total amount of glucose transporter protein in whole brain H~~~~~~, the K~ values for type 11 pneumocytes and lung and dial cell membranes, as measured by [3Hlcflochalasin-B fibroblasts were similar in all three groups (Table 1) Glut 1 was abundantly expressed in lung tissue, type I1 pneumocytes, and lung fibroblasts from SGA, sham, and normal fetuses. Northern and slot-blot analyses demonstrated that compared to normals, Glut 1 mRNA was diminished by approximately 50% ( p < 0.05) in uncultured lung tissue and cultured type I1 pneumocytes of SGA fetuses (Figs. 2 and 3 ). There was a 3-fold decline in Glut 1 mRNA abundance in lung fibroblasts. We were unable to detect Glut 3 mRNA signal in type I1 pneumocytes or uncultured lung tissue from SGA, sham, or normal fetuses.
To ensure that the decrease in Glut 1 mRNA in SGA fetal lungs was specific for the D-Glut mRNA, the samples were probed with the cDNA B-actin. There were no differences in B- Diminished somatic growth with normal brain growth is chardifferences were noted among the three groups.
actenstic of intrauterine growth retardation caused by uteropla- cental insufficiency and other maternal disorders during pregnancy. The mechanisms at the cellular level responsible for impairing somatic growth but sparing brain growth are poorly understood. Because glucose is an important metabolic fuel for the fetus, we reasoned that glucose transport might be related to these phenomena. Our study demonstrates that glucose transporter activity, protein, and gene expression are normal in SGA fetal brain and diminished in lung under conditions mimicking uteroplacental insufficiency. Because glucose provision is important for cell metabolism and growth, these observations indicate a link between differences in tissue glucose transport and the asymmetric organ growth in intrauterine growth retardation. We and others have found brain growth to be normal in SGA rat fetuses (1, 27) . This study indicates that total glucose transporter activity, protein, and Glut 1 expression are also normal in the SGA fetal rat brain. Brain tissue and glial cell 2-DG uptake, cytochalasin-B binding, and Glut 1 mRNA did not differ between SGA, sham, and normal fetuses. These observations indicate that the numerous metabolic and physiologic variables altered by maternal uterine artery ligation do not alter fetal brain glucose transport.
Brain Lung
The mechanisms responsible for normal glucose transporter activity, protein, and expression in the brain of SGA fetuses are unknown. Glucose transport might have been maintained as a result of sustained glucose availability. With maternal uterine artery ligation, glucose provision to the fetus is compromised; however, blood flow to the brain may be increased relative to other organs (28) . This may maintain provision of glucose to the brain and guarantee normal brain glucose transport and growth.
We found that maternal uterine artery ligation reduces both glucose transporter activity, protein, and mRNA in fetal lung, an organ in which growth is retarded. This technique results in transient decreases in fetal glucose and amino acid concentrations and altered gaseous exchange to the fetus. Cellular energy and redox states are transiently altered (29) , and plasma insulin and IGF concentrations are diminished (1, 2, 30, 31 ). The combination of these altered variables could affect glucose transport by tissue-specific regulation of glucose transporter gene expression, i.e. reducing lung but maintaining brain glucose transport. It should also be pointed out that cell glucose transport might not actually modulate fetal growth but merely reflect intrinsic growth. The alterations in physical factors resulting from uteroplacental insufficiency could modulate tissue metabolism, which in turn could reduce glucose transport.
How the alterations in fetal metabolism resulting from maternal uterine artery ligation affect fetal glucose transport is unclear. In the adult rat, limited glucose availability resulting from fasting decreases glucose transport in adipose tissue (32, 33) . Diminished insulin availability caused by streptozotocin treatment or fasting decreases adult rat muscle glucose transport (34) (35) (36) . Acidosis can impair glucose transporter function and produce insulin resistance (32, 34) . Little is known about the effects of these alterations on fetal glucose transporters.
Diminished glucose uptake in the SGA fetal lung could result from decreased Glut 1 gene expression or altered glucose transporter protein. We found that total glucose transporter protein as measured by cytochalasin-B binding and Glut 1 mRNA were similarly decreased in type I1 pneumocytes and lung fibroblasts of SGA, sham, and normal fetuses. However, the affinity of glucose transporters for glucose did not differ between SGA and normal lung. Therefore, the metabolic and physiologic variables altered in the SGA fetus appear to act at the transcriptional or posttranscriptional (altered mRNA stability) level rather than at the posttranslational level in lung.
Isoforms other than Glut 1 could contribute to fetal glucose uptake. Glut 3 has been found in small amounts in fetal and newborn rabbit brain (8) . Our data suggest that little Glut 3 (as measured by the mouse cDNA probe) is expressed in the fetal rat brain and even less is expressed in lung.
In vitro conditions could have affected measurements of cell glucose transport. We performed 2-DG studies in type I1 pneumocytes after 3 d and in glial cells after 7 d of culture. This difference was unavoidable because type I1 pneumocytes dedifferentiate with longer incubation. In contrast, the sufficient growth of glial cell monolayers requires at least 7 d, and dedifferentiation does not occur. Glucose transport was similar in SGA and normal uncultured brain tissue and in cultured glial cells. Glucose transport, cytochalasin-B binding and Glut 1 expression were similarly diminished in uncultured lung tissue and in cultured type 11 pneumocytes and lung fibroblasts from SGA fetuses. These similarities confirm that the in vitro conditions for cell monolayer culture did not alter the in vivo effects of maternal uterine artery ligation upon fetal brain and lung glucose transport.
These data suggest that under conditions of uteroplacental insufficiency, which results in numerous metabolic and physiologic alterations in the SGA fetus, glucose transport is differentially altered in the brain and lung. To the extent that glucose is an important metabolic fuel for the fetus, this limitation of glucose transport may affect the growth of such organs as the lung. The maintenance of glucose transport in the brain may be one mechanism to assure normal brain growth and may contribute to the brain sparing phenomenon seen in SGA fetuses.
